Sen­ate Fi­nance Chair Wyden con­tin­ues fight over low phar­ma tax rates, this time with BMS

Sen. Ron Wyden (D-OR) isn’t done dig­ging in­to the par­tic­u­lar­ly low tax rates for phar­ma com­pa­nies, and how their for­eign ops can low­er those bills.

In a three-page let­ter sent to Bris­tol My­ers Squibb CEO Gio­van­ni Caforio, Wyden sought more in­for­ma­tion on Bris­tol My­ers’ in­ter­na­tion­al tax prac­tices as the Sen­ate Fi­nance Com­mit­tee in­ves­ti­gates how phar­ma­ceu­ti­cal com­pa­nies who are based in the US can low­er its tax rates via “com­plex cross-bor­der tax avoid­ance strate­gies.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER